Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties.

Melina K Grasmeier,Susanne Weber,Matthias Treiber,Markus A Thaler,Peter B Luppa

Clinical chemistry and laboratory medicine（2023）

引用 0|浏览9

暂无评分

摘要

Overall, both SPR biosensor assays exhibited reliable quantitative performance with accuracies superior to their ELISA counterparts and precision inferior to ELISA only for ADAmon. DissR presented itself as promising ADA binding parameter and could contribute to both earlier and more tailored therapeutic decisions.

查看译文

关键词

anti-drug antibodies,biomolecular interaction analysis,inflammatory bowel disease,infliximab,surface plasmon resonance,therapeutic drug monitoring

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要